RxNorm 371304

cascara sagrada Oral Tablet

RxNorm Semantic Concepts

RxNorm semantic concepts for the RxCUI 371304 unique identifier include: cascara sagrada Oral Tablet (12258801).

RxNorm Atom ID: 12258801 - Semantic Clinical Drug Form
cascara sagrada Oral Tablet

RXCUI:
371304 - RxNorm Unique Identifier for a concept (Concept ID)
LAT:
ENG - Language of the Term
RXAUI:
12258801 - Unique identifier for the atom (RxNorm Atom ID)
Is Prescribable?
NO - This drug IS NOT part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States.
Concept Description:
cascara sagrada Oral Tablet - Description of concept identifier
Term Type (TTY):
SCDF - Term type in source with name and description
Term Type Name:
Semantic Clinical Drug Form - Name of term type in source
Term Type Description:
Ingredient + Dose Form - Description of term type in source
Code:
371304 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
Suppress Flag:
N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility.
CVF:
- Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
Source:
RXNORM - Concept source abbreviation
Source Name:
RxNorm Vocabulary - The official name for a source
Source Version:
20AA_240304F - The source version
Source Date:
March 04, 2024 - RxNorm data last updated
Source License Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information
Source Content Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information
Source Short Name:
RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server

* This product uses publicly available data courtesy of the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Patient Education

Cascara Sagrada


What is it? Cascara sagrada is a shrub. The dried bark is used to make medicine.

Cascara sagrada used to be approved by the U.S. Food and Drug Administration (FDA) as an over-the-counter (OTC) drug for constipation. However, over the years, concerns were raised about cascara sagrada's safety and effectiveness. The FDA gave manufacturers the chance to submit safety and effectiveness information to answer these concerns. But the companies decided the cost of conducting safety and effectiveness studies would likely be more than the profit they could expect from sales of cascara sagrada. So they didn't comply with the request. As a result, the FDA notified manufacturers to remove or reformulate all OTC laxative products containing cascara sagrada from the U.S. market by November 5, 2002. Today, you can buy cascara sagrada as a "dietary supplement", but not as a drug. "Dietary supplements" don't have to meet the standards that the FDA applies to OTC or prescription drugs.

Cascara sagrada is commonly used by mouth as a laxative for constipation.

In foods and beverages, a bitterless extract of cascara sagrada is sometimes used as a flavoring agent.

In manufacturing, cascara sagrada is used in the processing of some sunscreens.


[Learn More]


* Please review the disclaimer below.